Regarding the evidence-based use of micronized progesterone

An issue of habitual miscarriage poses a high social importance especially during COVID-19 pandemic. Meanwhile, healthcareworkers faced a mass media campaign against using micronized progesterone upon habitual miscarriage, which, as viewed by us, displays signs of prejudiced data manipulation and may disorient practitioners. In this Letter we provide objective information on accumulated data regarding gestagenes efficacy and safety. We invoke healthcare professionals to make decisions deserving independent primary source trust presented by original scientific papers published in peer-reviewed journals, clinical recommendations proposed by professional medical communities as well as treatment standards and protocols.

1. Obstetrics: national guideline. Eds. G. M. Savelyeva, G. T. Sukhikh, V. N. Serova, V. E. Radzinsky. [Akusherstvo: nacional’noe rukovodstvo. Pod red. G. M. Savel’evoj, G. T. Suhih, V. N. Serova, V. E. Radzinskogo. 2-e izd., pererab. i dop]. Moskva: GEOTAR-Media, 2018. 1088 s. (In Russ.).

2. Makatsariya A. D., Bitsadze V. O., Khizroeva J. Kh. et al. Novel coronavirus infection (COVID-19) and risk groups in obstetrics and gynecology. [Novaya koronavirusnaya infekciya (COVID-19) i gruppy riska v akusherstve i ginekologii]. Akusherstvo, Ginekologia i Reprodukcia. 2020;14(2):159–162. (In Russ.). https://doi.org/10.17749/2313-7347.133.

3. Makatsariya A. D., Grigorieva K. N., Mingalimov M. A. et al. Coronavirus disease (COVID-19) and disseminated intravascular coagulation. [Koronavirusnaya infekciya (COVID-19) i sindrom disseminirovannogo vnutrisosudistogo svertyvaniya]. Akusherstvo, Ginekologia i Reprodukcia. 2020;14(2):123–31. (In Russ.). https://doi.org/10.17749/2313-7347.132.

4. Coomarasamy A., Helen Williams H., Truchanowicz E. et al. A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med. 2015;373(22):2141–8. https://doi.org/10.1056/NEJMoa1504927.

5. Manuhin I. B., Dobrohotova E. Yu., Kuleshov V. M. et al. Therapy of threatened miscarriage with micronized progesterone and dydrogesterone (results of a multicenter open prospective comparative non-interventional study). [Lechenie ugrozhayushchego vykidysha preparatami mikronizirovannogo progesterona i didrogesterona (rezul’taty mnogocentrovogo otkrytogo prospektivnogo sravnitel’nogo neintervencionnogo issledovaniya)]. Problemy reprodukcii. 2018;24(3):34–42. (In Russ.). https://doi.org/10.17116/repro201824334.

6. Coomarasamy A., Devall A. J., Cheed V. et al. A randomized trial of progesterone in women with bleeding in early pregnancy. N Engl J Med. 2019;380(19):1815–24. https://doi.org/10.1056/NEJMoa1813730.

7. Order of the Government of RF dated October 12, 2019 N 2406-r. [Rasporyazhenie Pravitel’stva RF ot 12 oktyabrya 2019 g. № 2406-r]. Moskva, 2019. 261 s. (In Russ.).

8. Letter of the Health Ministry of Russia dated February 13, 2020 N 15-4/ I/368-07 On the direction of clinical guidelines “Normal pregnancy”. [Pis’mo Minzdrava Rossii ot 13 fevralya 2020 g. N 15-4/I/368-07 O napravlenii klinicheskih rekomendacij «Normal’naya beremennost’»]. Moskva, 2020. 89 s. (In Russ.).

9. Letter of the Ministry of Health of Russia dated December 17, 2013 N 15-4/10/2-9480 – On the direction of the clinical recommendations "Premature birth". [Pis'mo Minzdrava Rossii ot 17.12.2013 N 15-4/10/2-9480 – O napravlenii klinicheskih rekomendacij «Prezhdevremennye rody»]. Moskva, 2013. 35 p.

10. Letter of the Health Ministry of Russia dated 15.02.2019 г. N 15-4/И/2- 1218 – On the direction of clinical recommendations (treatment protocol) “Female infertility (modern approaches to diagnosis and treatment)”. [Pis’mo Minzdrava Rossii ot 15.02.2019 g. N 15-4/И/2-1218 – O napravlenii klinicheskih rekomendacij (protokola lecheniya) «Zhenskoe besplodie (sovremennye podhody k diagnostike i lecheniyu)»]. Moskva, 2019. 100 s. (In Russ.).

11. Letter of the Health Ministry of Russia dated December 28, 2018 N 15-4/10/2-7991 On clinical recommendations (treatment protocol) “Cervical incompetence”. [Pis’mo Minzdrava Rossii ot 28 dekabrya 2018 g. N 15-4/10/2-7991 O klinicheskih rekomendaciyah (protokole lecheniya) «Istmiko-cervikal’naya nedostatochnost’»]. Moskva, 2018. 29 s. (In Russ.).

12. Letter of the Health Ministry of Russia dated June 7, 2016 N 15-4/10/2- 3482 – On the direction of clinical recommendations (treatment protocol) “Miscarriage in early pregnancy: diagnosis and management tactics”. [Pis’mo Minzdrava Rossii ot 7 iyunya 2016 g. N 15-4/10/2-3482 – O napravlenii klinicheskih rekomendacij (protokola lecheniya) «Vykidysh v rannie sroki beremennosti: diagnostika i taktika vedeniya»]. Moskva, 2016. 19 s. (In Russ.).

13. Coomarasamy A., Devall A. J., Brosens J. J. et al. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence. Am J Obstet Gynecol. 2020;223(2):167–76. https://doi.org/10.1016/j.ajog.2019.12.006.

14. Conclusion of the Expert Council on the results of the 2nd World Congress of Medicine of Mother, Fetus and Newborn “Micronized progesterone in the treatment of miscarriage”. [Zaklyuchenie Ekspertnogo Soveta po itogam 2-go Vsemirnogo kongressa mediciny materi, ploda i novorozhdennogo «Mikronizirovannyj progesteron v lechenii nevynashivaniya»]. Problemy reprodukcii. 2019;25(2):46–50. (In Russ.). https://doi.org/10.17116/repro20192502146.

15. Siew J. Y.S., Allen J. C., Hui C. Y.Y. et al. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage. Eur J Obstet Gynecol Reprod Biol. 2018;228:319–24. https://doi.org/10.1016/j.ejogrb.2018.07.028.

16. Czajkowski K., Sienko J., Mogilinski M. et al. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril. 2007;87(3):613–8. https://doi.org/10.1016/j.fertnstert.2006.07.1506.

17. Da Fonseka E. B., Bittar R. E., Carvalho M. H.B., Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003;188(2):419–24. https://doi.org/10.1067/mob.2003.41.

18. Romero R., Conde-Agudelo A., Da Fonseca E. et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. Am J Obstet Gynecol. 2018;218(2):161–80. https://doi.org/10.1016/j.ajog.2017.11.576.

19. Dodd J. M., Jones L., Flenady V. et al. Prenatal administration of progesterone for preventing pretermbirth in women considered to be at risk of preterm birth. Cochrane Database Syst Rev. 2013;31(7):CD004947. https://doi.org/10.1002/14651858.CD004947.pub3.

20. Jarde A., Lutsiv O., Park C. K. et al. Effectiveness of progesterone, cerclage and pessary for preventing preterm birth in singleton pregnancies: a systematic review and network meta-analysis. BJOG. 2017;124(8):1176–89. https://doi.org/10.1111/1471-0528.14624.

21. Romero R., Conde-Agudelo A., El-Refaie W. et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated metaanalysis of individual patient data. Ultrasound Obstet Gynecol. 2017;49(3):303–14. https://doi.org/10.1002/uog.17397.

22. Farine D., Mundle W., Dodd J. The use of progesterone for prevention of preterm birth. J Obstet Gynaecol Can. 2008;30(1):67–71. https://doi.org/10.1016/S1701-2163(16)32716-5.

23. SMFM clinical guidelines. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol. 2012;206(5):376–86. https://doi.org/10.1016/j.ajog.2012.03.010.

24. FIGO Working Group on Best Practice in Maternal – Fetal Medicine. Best practice in maternal–fetal medicine. Int J Gynecol Obstet. 2015;128(1):80–2. https://doi.org/10.1016/j.ijgo.2014.10.011.

25. Di Renzo G. C., Cabero Roura L., Facchinetti F. et al. Preterm labor and birth management: recommendations from the European Association of Perinatal Medicine. J Matern Fetal Neonatal Med. 2017;30(17):2011–30. https://doi.org/10.1080/14767058.2017.1323860.

26. Hassan S., Romero R., Vidyadhari D. et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38(1):18–31. https://doi.org/10.1002/uog.901.

27. McNamara H.C., Wood R., Chalmers J. et al. (2015) STOPPIT Baby Follow-Up Study: The effect of prophylactic progesterone in twin pregnancy on childhood outcome. PLoS One. 2015;10(4):e0122341. https://doi.org/10.1371/journal.pone.0122341.

28. Coomarasamy A., Williams H., Truchanowicz E. et al. A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med. 2015;373(22):2141–8. https://doi.org/10.1056/NEJMoa1504927.

29. Norman J. E., Marlow N., Messow C-M. et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet. 2016;387(10033):2106–6. https://doi.org/10.1016/S0140-6736(16)00350-0.

30. Ovarian stimulation for IVF/ICSI. Guideline of the European Society of Human Reproduction and Embryology. ESHRE Reproductive Endocrinology Guideline Group, 2019. 136 p. Available at: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Ovarian-Stimulation-in-IVF-ICSI. [Accessed: 16.07.2020].

31. Romero R., Stanczyk F. Z. Progesterone is not the same as 17-hydroxyprogesterone caproate: implications for obstetrical practice. Am J Obstet Gynecol. 2013;208(6):421–6. https://doi.org/10.1016/j.ajog.2013.04.027.

32. Romero R., Yeo L., Miranda J. et al. A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix. J Perinat Med. 2013;41(1):27–44. https://doi.org/10.1515/jpm-2012-0272.

33. Meis P. J., Klebanoff M., Thom E. et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):2379–85. https://doi.org/10.1056/NEJMoa035140.

34. Zaqout M., Aslem E., Abuqamar M. et al. The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy. Pediatr Cardiol. 2015;36(7):1483–8. https://doi.org/10.1007/s00246-015-1190-9.

35. Zaqout M., Aslem E., Abuqamar M. et al. Association between oral intake of dydrogesterone during early pregnancy and congenital heart disease: a case-control study. Lancet. 2017;390:S8. https://doi.org/10.1016/s0140-6736(17)32059-7.

36. Koren G. Dydrogesterone exposure in the first trimester of pregnancy and fetal malformations. Motherisk Int J. 2020;1:11.